China's NMPA Releases 9th Batch of AI Supervision 'Two Libraries' for Remote Diagnostic Devices

On April 27, 2026, China’s National Medical Security Administration (NMSA) published the ninth batch of its intelligent medical insurance supervision ‘knowledge base + rule base’ (‘two libraries’), introducing clinical usage standards and quality control requirements for 12 categories of diagnostic equipment—including remote ultrasound, AI-assisted pathology analysis, and portable ECG devices. This update signals heightened regulatory alignment between domestic clinical governance and overseas market access, particularly for exporters of remote diagnostic devices targeting emerging markets such as Singapore and Saudi Arabia.

Event Overview

On April 27, 2026, the National Medical Security Administration (NMSA) publicly released the ninth batch of its intelligent supervision ‘knowledge base + rule base’. The update includes clinical usage specifications and quality control points for 12 types of diagnostic equipment: remote ultrasound systems, AI-assisted pathology analysis tools, and portable electrocardiogram (ECG) devices, among others. The NMSA confirmed that regulatory authorities in Singapore (Health Sciences Authority, HSA) and Saudi Arabia (Saudi Food and Drug Authority, SFDA) are referencing these ‘two libraries’ in their product review processes. Exporters of remote diagnostic devices must now align with both China’s clinical regulatory logic and overseas registration requirements to achieve ‘single development, dual-market access’.

Industries Affected

Export-Oriented Medical Device Manufacturers

These enterprises are directly impacted because the NMSA’s clinical usage norms—though developed for domestic reimbursement oversight—are now being cited by foreign regulators as part of technical evaluation. Compliance with the ‘two libraries’ is no longer optional for market entry into jurisdictions adopting them as reference material.

Regulatory Affairs & Clinical Strategy Teams

Professionals responsible for global registration pathways must now integrate China’s clinical utilization logic—not just safety and performance data—into pre-submission planning. The ‘two libraries’ introduce new expectations around real-world clinical deployment, operator training, and output validation, which may affect labeling, instructions for use, and post-market surveillance plans.

Supply Chain & Quality Assurance Providers

Third-party QA auditors, certification bodies, and contract manufacturers supporting export-oriented device firms face increased scrutiny on documentation traceability—particularly regarding how clinical workflows (e.g., remote interpretation protocols or AI result verification steps) are embedded into design history files and risk management dossiers.

What Enterprises and Practitioners Should Focus On Now

Monitor official cross-references and implementation guidance

While Singapore HSA and Saudi SFDA have indicated use of the ‘two libraries’ as a reference, neither has formally adopted them as binding requirements. Enterprises should track official statements from these agencies—and any subsequent guidance documents—to distinguish between informal benchmarking and enforceable obligations.

Prioritize clinical workflow documentation for high-impact device categories

The 12 newly covered device types (e.g., remote ultrasound, AI-assisted pathology tools) represent priority areas. Firms should audit existing clinical evaluation reports and usability studies to ensure alignment with the NMSA’s specified clinical use cases, operator qualifications, and output verification steps outlined in the ninth batch.

Differentiate between policy signal and operational impact

This release reflects an evolving convergence of reimbursement logic and regulatory review—not an immediate change in CE marking, FDA 510(k), or GCC conformity assessment criteria. Companies should avoid overhauling submissions prematurely; instead, treat it as a forward-looking indicator for upcoming clinical evidence expectations in bilateral technical consultations.

Update internal alignment between R&D, regulatory, and clinical teams

Since the ‘two libraries’ emphasize real-world clinical integration (e.g., how AI outputs are validated before diagnosis), cross-functional coordination—especially between software development, clinical affairs, and regulatory strategy—is essential. Firms should initiate internal gap assessments focusing on traceability from algorithm design to documented clinical decision support workflows.

Editorial Perspective / Industry Observation

Observably, this ninth batch functions primarily as a regulatory signaling mechanism—not yet a binding compliance requirement outside China. Its significance lies not in immediate enforcement, but in the precedent it sets: domestic clinical governance frameworks are gaining traction as international technical benchmarks. Analysis shows that this trend reflects a broader shift where health technology assessment (HTA) criteria, reimbursement logic, and clinical utility expectations increasingly inform pre-market review—especially in middle-income markets seeking efficient, evidence-informed evaluation pathways. From an industry perspective, the ‘two libraries’ are better understood as an early-stage harmonization vector rather than a standalone standard. Continuous monitoring is warranted, particularly as more ASEAN and GCC regulators cite similar references in public consultation drafts.

In summary, the NMSA’s ninth batch of the ‘two libraries’ does not impose new legal obligations on exporters—but it does redefine the evidentiary landscape for clinical credibility in key growth markets. It is not a regulation, nor a certification hurdle; rather, it is an emerging reference point shaping how clinical value and safe integration of remote diagnostics are assessed globally. Current interpretation should focus on strategic preparedness—not urgent compliance action.

Source: National Medical Security Administration (NMSA) official announcement, April 27, 2026. Note: Ongoing observation is recommended for formal adoption status by Singapore HSA and Saudi SFDA, as neither agency has issued binding implementation rules referencing the ‘two libraries’ at time of publication.